Ann: In-licencing of Phase II-ready molecule - presentation-NRT.AX, page-17

This is a good change for Novogen IMO. While I agree we are now going to be burning cash at a higher rate we also get a PII ready GBM drug that I expect they would somehow bring the Trilexium GBM drug features to influence! Otherwise it would be a waste of that work done on our already well tested GBM that does cross the BBB. Buying a company that has all the functions, you'd hope, to manage this PII test is smart as it allows us to continue with Cantrixil without stressing the science teams...

I like this purchase!

Wonder if Eleanor is still with us?? from ann June 4, 2015:
　
Eleanor Ager PhD, Novogen GBM Program Manager, said, "TRXE-009 shows remarkably potent killing in the test tube against a wide range of cancer types, but it has been its particularly potent activity against brain cancers including glioblastoma and DIPG that has marked it as a potential treatment of primary brain cancers in both adults in children. These are tumors that show high levels of resistance to standard of care drugs, so even if it was possible to get those drugs into the brain, they may not offer clinical benefit."